Free Trial
NASDAQ:AXDX

Accelerate Diagnostics Q4 2024 Earnings Report

Accelerate Diagnostics logo
$0.13 -0.33 (-71.40%)
As of 02:19 PM Eastern

Accelerate Diagnostics EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.50
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Accelerate Diagnostics Revenue Results

Actual Revenue
$2.82 million
Expected Revenue
$3.00 million
Beat/Miss
Missed by -$184.00 thousand
YoY Revenue Growth
N/A

Accelerate Diagnostics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Friday, March 21, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Accelerate Diagnostics' Q1 2025 earnings is scheduled for Wednesday, May 14, 2025, with a conference call scheduled on Thursday, May 15, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Accelerate Diagnostics Earnings Headlines

Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by StockNews.com
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More Accelerate Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Accelerate Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Accelerate Diagnostics and other key companies, straight to your email.

About Accelerate Diagnostics

Accelerate Diagnostics (NASDAQ:AXDX), an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

View Accelerate Diagnostics Profile

More Earnings Resources from MarketBeat